Fluorodeoxyglucose, sodium fluoride, and prostate-specific membrane antigen positron emission tomography studies for treatment response assessment in prostate cancer

ABSTRACT
Various positron emission tomography (PET) studies are available for prostate cancer which show various successes at demonstrating primary, recurrent, or metastatic tumor and assessing response to treatment. In this case report, we will present and compare pre- and post-therapy fluorodeoxyglucose, sodium fluoride, and gallium-68 prostate-specific membrane antigen PET images of a patient with prostate cancer.

Keywords: Fluorodeoxyglucose, gallium-68 prostate-specific membrane antigen, prostate cancer, sodium fluoride, treatment response assessment

INTRODUCTION
Prostate cancer is the most common cancer and the third most cause for cancer-associated death in men.[1] Various positron emission tomography (PET) studies are available for prostate cancer which target various molecules, metabolisms, synthesis, or receptors with various degrees of success at detecting primary tumor and metastatic disease and assessing response to treatment. Among these, F-18 fluorodeoxyglucose (FDG) assesses the glucose metabolism, F-18 sodium fluoride (NaF) evaluates osteoblastic activity, radiolabeled choline (F-18 choline or C-11 choline) is a marker of cell membrane proliferation which is phosphorylated by choline kinase to form phosphorylcholine, followed by generation of phosphatidylcholine membrane microdomains following conversion to acetyl-CoA and then to fatty acids, F-18 fluoro-5α-dihydrotestosterone binds to androgen receptors, C-11 methionine assesses the amino acid transport and protein synthesis, F-18 fluciclovine assesses the amino acid transport, and gallium-68 prostate-specific membrane antigen (Ga-68 PSMA) ligand has high affinity to human PSMA.

Bone scan is widely used in the management of prostate cancer in the detection of bone metastases. Currently, NaF PET/computed tomography (CT) bone scan has significantly replaced standard bone scintigraphy. Ga-68 PSMA ligand PET/CT has gained high attention for accurate staging of primary prostate cancer and restaging after biochemical recurrence.[2-4] FDG PET/CT is not commonly used in prostate cancer and its use is limited to staging patients with aggressive primary tumors or localizing the site of disease in a small fraction of patients with biochemical failure and negative conventional imaging studies.[5] FDG-PET is useful for assessing response...
to treatment and prognosis in patients with castrate-resistant metastatic prostate cancer.\textsuperscript{5-7}

In this article, we will present FDG, NaF, and PSMA PET/CT images to assess response to treatment in a patient with prostate cancer.

**CASE REPORT**

A 71-year-old male initially presented with elevated prostate-specific antigen (PSA) of 190 ng/ml and multiple lung nodules on CT of the chest in June 2015. Biopsy from the prostate gland was performed. FDG PET/CT study 2 days after the biopsy showed hypermetabolic nodule in the left lung with SUVmax of 1.9, which further increased to 5.5 on delayed images and heterogeneously increased bone marrow uptake which was suspicious for diffuse bone metastases and moderate uptake in the prostate gland (SUVmax: 5.8) \cite{5-7} [Figures 1 and 2]. Biopsy result from the prostate gland was consistent with prostate cancer. NaF PET in July 2015 showed widespread bone metastasis [Figure 1]. Clinical stage based on PET and radiological studies was T3bN1M1. The patient was placed on chemotherapy. PSA became 4.4 ng/ml with chemotherapy, but it was stopped in February 2016, due to liver toxicity, and hormone therapy (HT) was started. Because of rising PS (10 ng/ml), while on HT, FDG and NaF PET studies were ordered in May 2016. FDG PET showed resolution of uptake in the lung nodule and significant reduction of the bone marrow hypermetabolic activity but persistent uptake in the prostate gland (SUVmax: 8.4) [Figures 1 and 2]. NaF PET/CT study showed widespread bone metastasis with slight reduction in osteoblastic activity of some lesions with overall stability in other lesions as compared to prechemotherapy NaF PET/CT scan [Figure 1]. To better assess residual disease, Ga-68 PSMA PET/CT scan was also obtained which showed uptake in the prostate gland as well as in several bones and pelvic lymph nodes [Figures 1 and 2]. The patient continued to receive HT, but PSA continued to rise to 99 ng/ml. Ga-68 PSMA PET/CT study in November 2016 showed the progression of disease with increase in the number of metastatic lesions in the bone and lymph nodes with diffuse uptake in the prostate gland [Figures 1 and 2]. The patient was referred to another hospital for Lu-177 PSMA treatment.

**DISCUSSION**

In our patient with widespread bone metastases on NaF PET scan, there was only mild reduction with mainly persistent osteoblastic activity after chemotherapy. Based on NaF PET images only, we can say findings are due mild response to treatment with significant residual disease. However, when comparing and correlating postchemotherapy NaF with FDG PET which showed significant reduction in metabolic activity of bone and bone marrow disease, we can now say that significant portion of persistent osteoblastic activity on NaF PET is likely due to bone repair in the region of the

![Figure 1: Fluorodeoxyglucose, sodium fluoride, and prostate-specific membrane antigen positron emission tomography maximum intensity projection images before and after treatment](image-url)
treated disease or decreasing flare uptake 3 months after chemotherapy. On the other hand, FDG PET findings (mild residual bone and bone marrow activity) cannot determine whether there is mild residual disease or reactive bone marrow changes. Obtaining Ga-68 PSMA PET study helped to confirm the amount of residual disease in this patient. However, it would be valuable to have a prechemotherapy Ga-68 PSMA PET and compare the amount of metastatic disease in bone and soft tissues with the extent of the disease identified on prechemotherapy FDG and NaF PET studies.

Bone scans, either with NaF PET or bone scintigraphy, have limited value at evaluating response to treatment as they show the osteoblastic reaction or response to tumor infiltration, not the tumor itself. Osteoblastic activity as a result of bone healing or flare response can cause false-positive diagnosis of disease progression or residual disease.[8-11] Flare response is considered when metastases on bone scan remain stable or show progression despite other parameters indicate response to treatment. Flare is probably caused by an increase in blood flow due to an inflammatory response or an increased turnover of hydroxyapatite in the new bone laid down as part of the healing process.[12] Flare phenomenon lasts 6–12 months after chemotherapy.

Recent studies showed promising results with Ga-68 PSMA ligand in detecting metastatic disease in both soft tissues and bone.[14-18] In a patient with bone metastases and progression after Ra-223 treatment on both Ga-68 PSMA and NaF PET, it was not clear if the increased uptake was due to flare or disease progression on NaF PET.[17] Authors suggested that Ga-68 PSMA PET may be superior to F-18 NaF PET for the evaluation of therapy response to Ra-223 therapy in bone metastases. In a recent study, Ga-68 PSMA-11 PET resulted in a major change in management in 53% of patients with biochemical recurrence.[18] In patients with PSA levels below 0.2 ng/dL, 7 of 12 patients had disease detected on PSMA PET scan, five of whom had a major change in management in the same study.

CONCLUSION

In our patient with prostate cancer and extensive bone metastases who had multiple PET images before and after treatment, NaF PET was clearly superior to FDG PET for demonstrating amount of bone metastasis. On the other hand, FDG PET provided a better result than NaF PET for assessing response to treatment, but PSMA PET was superior to both NaF and FDG PET studies for demonstrating amount
of residual disease. It appears that Ga-68 PSMA PET is helpful in differentiating flare from stable or progressive metastatic bone disease in cases with indeterminate bone scan.

Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habel G, Kopka K, et al. (68) Ga-PSMA-11 PET/CT: A new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 2016;43:34-41.
3. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68) Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:34-41.
4. Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, et al. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 2015;36:582-7.
5. Jadvar H. Is there use for FDG-PET in prostate cancer? Semin Nucl Med 2016;46:502-6.
6. Zukotynski KA, Kim CK, Gerbardo VH, Hainer J, Taplin ME, Kantoff P, et al. (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. Am J Nucl Med Mol Imaging 2014;5:72-82.
7. Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, et al. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs 2011;29:1465-74.
8. Levenson RM, Sauerbrunn BJ, Bates HR, Newman RD, Eddy JL, Hilde DC. Comparative value of bone scintigraphy and radiography in monitoring tumor response in systemically treated prostatic carcinoma. Radiology 1983;146:513-8.
9. Pollen JJ, Witztum KE, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol 1984;142:773-6.
10. Ciray I, Aström G, Andréasson I, Edeking T, Hansen J, Bergh J, et al. Evaluation of new sclerotic bone metastases in breast cancer patients during treatment. Acta Radiol 2000;41:178-82.
11. Scher HI. Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer 2003;97 3 Suppl: 758-71.
12. Messiou C, Cook G, deSouza NM. Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer 2009;101:1225-32.
13. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Tanikawa K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32:1253-8.
14. Afshar-Oromieh A, Zeichmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with at(68) Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41:11-20.
15. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Hallet B, Weirich G, et al. Diagnostic efficacy of (68) Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 2016;195:1436-43.
16. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Hallet B, et al. Evaluation of hybrid 68Ga-PSMA Ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015;56:668-74.
17. Uprimny C, Kroiss A, Nilica B, Buxbaum S, Dechristoforo C, Horninger W, et al. (68)Ga-PSMA ligand PET versus (18)F-NaF PET. Evaluation of response to (223)Ra therapy in a prostate cancer patient. Eur J Nucl Med Mol Imaging 2015;42:362-3.
18. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg M, et al. Impact of Ga-68 PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med 2017; pii: jnumed.117.192476.